MENU

BT


HOME > INDUSTRIES > BT
  • Korea’s BT Industry

    Building on active government support and global technology development, growing demand for medical services by the aging population, and activity in the bio-generic field, the South Korean biotechnology (BT) industry has been enjoying continuous growth.

    GROWTH TREND OF BIO INDUSTRY IN KOREA

    Related Content Download

  • Korea’s BT Industry

    MARKET SIZE & NO. OF BIOTECH COMPANY

  • Korea’s BT Industry

    STEM CELL THERAPEUTICS

    13 clinical trial under way regarding DNA therapeutics
    7 global clinical under way
  • Korea’s BT Industry

    DNA THERAPEUTICS

    Company Disease Ongoing Stage Country
    Lower limb ischemia 2nd phase complete USA

     

     

     

    Diabetic neuropathy 3nd phase approved China

     

     

     

    Lou Gehrig's disease 1/2 phase ongoing USA

     

     

     

    Cardiac infarction 1/2 phase approved USA

     

     

     

     

    Liver cancer 3rd phase approved USA

     

     

     

     

    Degenerative Arthritis 3rd phase approved USA
  • Competitiveness of Seoul’s BT Industry

    Home to the top five general and university hospitals in South Korea, Seoul has become the top clinical trial city in the world (South Korea as a nation is 10th place) and is fast becoming a major destination for clinical trials.

    CLINICAL TRIALS BY CITY

    COUNTRY PROPORTION COUNTRY PROPORTION

     

     

     

     

    Seoul 1.04 New York 0.78

     

     

     

     

    Houston 0.78 Madrid 0.77

     

     

     

     

    London 0.64 Barcelona 0.64

     

     

     

     

    Dallas 0.60 Berlin 0.59

     

     

     

     

    Boston 0.58
  • Competitiveness of Seoul’s BT Industry

    GREAT INFRASTRUCTURE FOR CLINICAL TRIAL

    SAMSUNG MEDICAL CENTER
    SEOUL NATIONAL UNIVERSITY HOSPITAL
    KOREA UNIVERSITY MEDICAL CENTER
    SEVERANCE HOSPITAL
    AJOU UNIVERSITY HOSPITAL
    ASAN MEDICAL CENTER
    The highest number of pharmaceutical clinical trials in the world since 2012(Korea ranked the 10th as a country)
    Among 10 Korean government –assigned “research-focus-hospital”, 6 of them are located in Seoul
  • The Korean Market, The Global Pharmaceutical Companies’ Preferred Destination

    Novartis
    Entered the Korean market in 1984. Recording a steady, high growth rate as the world’s number 4 pharmaceutical company. Competitive in pharmaceuticals, vaccines, generic drugs (Sandos), etc.

    MSD
    Entered the Korean market in 1994. Strengthened its organization by merger of Merck (the head office of MSD Korea) with Schering-Plough in 2009. Developing innovative pharmaceuticals, vaccines, biotherapeutics, etc.

    MERCK
    Entered the Korean market in 1985. Leading the biopharmaceuticals and chemicals industries with its innovative, advanced technology for the highest quality. Merck Group in Korea consists of Merch Ltd., registered in 1989, and Merck Advanced Technologies Ltd., established in 2002

    SANOFI
    Entered the Korean market in 1991. Growing based on its six key items: emerging markets, vaccines, consumer healthcare, diabetes, drugs and medical supplies, and veterinary drugs.

  • Korea’s BT Industry

    Building on active government support and global technology development, growing demand for medical services by the aging population, and activity in the bio-generic field, the South Korean biotechnology (BT) industry has been enjoying continuous growth.

    GROWTH TREND OF BIO INDUSTRY IN KOREA

    Related Content Download

  • Korea’s BT Industry

    MARKET SIZE & NO. OF BIOTECH COMPANY

  • Korea’s BT Industry

    STEM CELL THERAPEUTICS

    13 clinical trial under way regarding DNA therapeutics
    7 global clinical under way
  • Korea’s BT Industry

    DNA THERAPEUTICS

    Company Disease Ongoing Stage Country
    Lower limb ischemia 2nd phase complete USA

     

     

     

    Diabetic neuropathy 3nd phase approved China

     

     

     

    Lou Gehrig's disease 1/2 phase ongoing USA

     

     

     

    Cardiac infarction 1/2 phase approved USA

     

     

     

     

    Liver cancer 3rd phase approved USA

     

     

     

     

    Degenerative Arthritis 3rd phase approved USA
  • Competitiveness of Seoul’s BT Industry

    Home to the top five general and university hospitals in South Korea, Seoul has become the top clinical trial city in the world (South Korea as a nation is 10th place) and is fast becoming a major destination for clinical trials.

    CLINICAL TRIALS BY CITY

    COUNTRY PROPORTION COUNTRY PROPORTION

     

     

     

     

    Seoul 1.04 New York 0.78

     

     

     

     

    Houston 0.78 Madrid 0.77

     

     

     

     

    London 0.64 Barcelona 0.64

     

     

     

     

    Dallas 0.60 Berlin 0.59

     

     

     

     

    Boston 0.58
  • Competitiveness of Seoul’s BT Industry

    GREAT INFRASTRUCTURE FOR CLINICAL TRIAL

    SAMSUNG MEDICAL CENTER
    SEOUL NATIONAL UNIVERSITY HOSPITAL
    KOREA UNIVERSITY MEDICAL CENTER
    SEVERANCE HOSPITAL
    AJOU UNIVERSITY HOSPITAL
    ASAN MEDICAL CENTER
    The highest number of pharmaceutical clinical trials in the world since 2012(Korea ranked the 10th as a country)
    Among 10 Korean government –assigned “research-focus-hospital”, 6 of them are located in Seoul
  • The Korean Market, The Global Pharmaceutical Companies’ Preferred Destination

    Novartis
    Entered the Korean market in 1984. Recording a steady, high growth rate as the world’s number 4 pharmaceutical company. Competitive in pharmaceuticals, vaccines, generic drugs (Sandos), etc.

    MSD
    Entered the Korean market in 1994. Strengthened its organization by merger of Merck (the head office of MSD Korea) with Schering-Plough in 2009. Developing innovative pharmaceuticals, vaccines, biotherapeutics, etc.

    MERCK
    Entered the Korean market in 1985. Leading the biopharmaceuticals and chemicals industries with its innovative, advanced technology for the highest quality. Merck Group in Korea consists of Merch Ltd., registered in 1989, and Merck Advanced Technologies Ltd., established in 2002

    SANOFI
    Entered the Korean market in 1991. Growing based on its six key items: emerging markets, vaccines, consumer healthcare, diabetes, drugs and medical supplies, and veterinary drugs.